{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:18:38Z","timestamp":1787494718749,"version":"build-2736575974"},"reference-count":41,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund (FWF)","doi-asserted-by":"publisher","award":["P32470-B"],"award-info":[{"award-number":["P32470-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Basophilia is a crucial prognostic variable in Ph-chromosome-positive chronic myeloid leukemia (CML). The ectoenzyme CD203c is an activation-linked surface antigen that is expressed specifically on basophil-committed progenitor cells and mature basophils. We examined the expression of CD203c on progenitors and\/or basophils in 21 healthy donors and 44 patients with CML. As expected, the numbers of CD203c+ blood leukocytes were significantly higher in CML patients compared to controls (percentage of CD203c+ cells among viable cells in CML at diagnosis: 4.19 \u00b1 3.68% vs. controls: 0.53 \u00b1 0.23%, p &lt; 0.05). Moreover, CML basophils expressed higher levels of CD203c compared to normal basophils (median staining-index in CML at diagnosis: 29.41 \u00b1 19.14 versus controls: 20.44 \u00b1 13.45). We also found that the numbers and percentage of circulating CD203c+ cells at diagnosis correlate with the disease-related risk-profile. Incubation of CML basophils with an anti-IgE-antibody resulted in further upregulation of CD203c. After successful treatment with imatinib and\/or other BCR::ABL1 inhibitors leading to major or complete molecular responses, the numbers of CD203c+ basophils decreased substantially in our CML patients compared to pre-treatment values. Together, CD203c is overexpressed on CML basophils, is further upregulated by IgE receptor cross-linking, and may serve as a biomarker to quantify basophilia in patients with CML at diagnosis and during therapy.<\/jats:p>","DOI":"10.3390\/cells12010003","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T04:45:53Z","timestamp":1671511553000},"page":"3","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph+ Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"12","author":[{"given":"Irina","family":"Sadovnik","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-4224","authenticated-orcid":false,"given":"Daniel","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravka","family":"Smiljkovic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Stefanzl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Degenfeld-Schonburg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Herndlhofer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Eisenwort","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, 1140 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Hauswirth","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer","family":"Sliwa","sequence":"additional","affiliation":[{"name":"Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, 1140 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Keil","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, 1140 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5095","authenticated-orcid":false,"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.hoc.2004.03.005","article-title":"Accelerated and blastic phases of chronic myelogenous leukemia","volume":"18","author":"Giles","year":"2004","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_8","first-page":"S31","article-title":"Advanced CML: Therapeutic options for patients in accelerated and blast phases","volume":"6","author":"Shah","year":"2008","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.14694\/EdBook_AM.2015.35.e381","article-title":"Diagnosing and managing advanced chronic myeloid leukemia","volume":"35","author":"Deininger","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","article-title":"Management of CML-blast crisis","volume":"29","author":"Hehlmann","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.V60.1.113.113","article-title":"Basophil production in myeloproliferative disorders: Increases during acute blastic transformation of chronic myeloid leukemia","volume":"60","author":"Denburg","year":"1982","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","article-title":"Characteristics of accelerated disease in chronic myelogenous leukemia","volume":"61","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","first-page":"978","article-title":"Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: The main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML","volume":"84","author":"Steegmann","year":"1999","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/10428190701858849","article-title":"Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia","volume":"49","author":"Valent","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e13000","DOI":"10.1111\/eci.13000","article-title":"The underestimated role of basophils in Ph+ chronic myeloid leukemia","volume":"48","author":"Valent","year":"2018","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdm343","article-title":"Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571)","volume":"18","author":"Agis","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_19","first-page":"354","article-title":"Serum-tryptase at diagnosis: A novel biomarker improving prognostication in Ph(+) CML","volume":"5","author":"Sperr","year":"2014","journal-title":"Am. J. Cancer Res."},{"key":"ref_20","first-page":"2343","article-title":"The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors","volume":"94","author":"Simmons","year":"1999","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood.V97.10.3303","article-title":"The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase\/phosphodiesterase 3","volume":"97","author":"Seiffert","year":"2001","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000057747","article-title":"Detection of novel CD antigens on the surface of human mast cells and basophils","volume":"127","author":"Ghannadan","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1067\/mai.2002.125257","article-title":"Recombinant allergens promote expression of CD203c on basophils in sensitized individuals","volume":"110","author":"Hauswirth","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000077351","article-title":"The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis","volume":"133","author":"Buehring","year":"2004","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/039463200802100404","article-title":"CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking","volume":"21","author":"Hauswirth","year":"2008","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1593\/neo.12724","article-title":"Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: A novel mechanism of BCR-ABL1-independent disease progression","volume":"14","author":"Ghanim","year":"2012","journal-title":"Neoplasia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2017.15","article-title":"Proposed diagnostic criteria and classification of basophilic leukemias and related disorders","volume":"31","author":"Valent","year":"2017","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2362.2009.02184.x","article-title":"Elevated tryptase levels selectively cluster in myeloid neoplasms: A novel diagnostic approach and screen marker in clinical haematology","volume":"39","author":"Sperr","year":"2009","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/17474086.2014.955008","article-title":"The serum tryptase test: An emerging robust biomarker in clinical hematology","volume":"7","author":"Valent","year":"2014","journal-title":"Exp. Rev. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/039463200702000207","article-title":"Interleukin-3 promotes the expression of E-NPP3\/CD203C on human blood basophils in healthy subjects and in patients with birch pollen allergy","volume":"20","author":"Hauswirth","year":"2007","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Smiljkovic, D., Herrmann, H., Sadovnik, I., Gamperl, S., Berger, D., Stefanzl, G., Eisenwort, G., Hoermann, G., Kopanja, S., and Dorofeeva, Y. (J. Allergy Clin. Immunol., 2022). Expression and Regulation of Siglec-6 (CD327) on Human Mast Cells and Basophils, J. Allergy Clin. Immunol., in press.","DOI":"10.1016\/j.jaci.2022.07.018"},{"key":"ref_32","first-page":"141","article-title":"Basophils exhibit rearrangement of the bcr gene in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"2","author":"Bosma","year":"1988","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.V73.3.777.777","article-title":"Basophils (Bsp-1+) derive from the leukemic clone in human myeloid leukemias involving the chromosome breakpoint 9q34","volume":"73","author":"Bodger","year":"1989","journal-title":"Blood"},{"key":"ref_34","unstructured":"Swerdlow, S.H., Campo, E., and Harris, N.L. (2008). Chronic myelogenous leukemia, BCR\/ABL1 positive. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press. [4th ed.]."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European LeukemiaNet. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hon.792","article-title":"Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management","volume":"24","author":"Martinelli","year":"2006","journal-title":"Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Cross","year":"2009","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2010.035006","article-title":"CD34(+)\/CD38(\u2212) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin","volume":"97","author":"Herrmann","year":"2012","journal-title":"Haematologica"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/3\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:44:36Z","timestamp":1760147076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cells12010003"],"URL":"https:\/\/doi.org\/10.3390\/cells12010003","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]}}}